Latest Neurizon Therapeutics News & Updates
See the latest news and media coverage for Neurizon Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing neurodegenerative disease treatments
neurizon.com- Headquarters
- Melbourne, Australia
- Company type
- Public company
- Number of employees
- 2–15
Last updated
Latest news about Neurizon Therapeutics
In short: Neurizon Therapeutics advanced its lead ALS candidate NUZ-001 into a Phase 2/3 trial and secured $44 million in funding to support its development.
Company announcements
-
Neurizon Therapeutics welcomes Dr Ross Murdoch as Independent Non-Executive Director
His extensive experience strengthens the Board for clinical execution and growth. The company thanks Dr Michael Thurn for his contributions.
-
Neurizon Therapeutics announces new preclinical data on NUZ-001
NUZ-001 increases activity in protein clearance pathways like autophagy and proteasomal system in neuronal models. Findings support its profile for ALS treatment in HEALEY trial.
-
Neurizon Therapeutics doses first participant with NUZ-001
This occurs in Regimen I of the HEALEY ALS Platform Trial, a Phase 2/3 study evaluating NUZ-001 in 160 participants across US ALS centers.
-
Neurizon secures $6 million R&D tax rebate
The rebate reflects 48.5% on eligible FY2025 activities. Net cash of $4.35 million received after loan repayment. Funds support HEALEY ALS Platform Trial.
Media coverage
-
Biotech Neurizon launches $11.3m shortfall auction after rights issue
The deal is aiming to cover the shortfall from a $17.1 million pro rata non-renounceable entitlement offer announced on December 23.
-
New data builds Neurizon's scientific case for lead drug candidate in ALS
Neurizon Therapeutics has released new preclinical findings that further characterise the biological mechanism of action (MOA) for lead compound NUZ-001, increasing the understanding of how...
-
Neurizon Therapeutics (ASX:NUZ) Rises as New Data Strengthens Case for ALS Drug Candidate
Neurizon Therapeutics (ASX:NUZ) Rises as New Data Strengthens Case for ALS Drug Candidate...
-
Neurizon advances ALS drug program as funding, trials and global partnerships gain momentum - Biotech
Neurizon Therapeutics (ASX:NUZ) has entered the second half of financial year 2026 in an acceleration phase, advancing its lead drug candidate while strengthening the financial...
Track Neurizon Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Neurizon Therapeutics competitors & trending companies
Browse news for competitors to Neurizon Therapeutics and other trending companies.
Transposon Therapeutics
Revalesio
Acelot
AlzeCure Pharma
Vesalic
Mitochon Pharmaceuticals
NRG Therapeutics
Verge Genomics
NeuroSense Therapeutics
Aquilus Pharmaceuticals
Canurta Therapeutics
Aperture Therapeutics
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media